BridgeMD
Compares treatment options for Neuromuscular Blockade
Official title Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults
ClinicalTrials.gov ID: NCT07446309
What this study is testing
What is HRS-9190; under Inhalational Anesthesia?
HRS-9190; under Inhalational Anesthesia is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for neuromuscular blockade.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Able and willing to provide a written informed consent
- people requiring elective general anesthesia surgery
- Meet specified age and body mass index (BMI) criteria
- Conform to the ASA Physical Status Classification
- Use of highly effective contraception for a specified period if applicable
You likely can't join if
- Scheduled for specific high-risk surgical procedures
- History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
- History of conditions affecting drug metabolism or anesthesia risk
- Abnormal laboratory values indicating significant clinical abnormalities
- Positive serology for specified infectious diseases
- Known hypersensitivity to related medications
See the full eligibility criteria
- Able and willing to provide a written informed consent
- people requiring elective general anesthesia surgery
- Meet specified age and body mass index (BMI) criteria
- Conform to the ASA Physical Status Classification
- Use of highly effective contraception for a specified period if applicable
- Scheduled for specific high-risk surgical procedures
- History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders
- History of conditions affecting drug metabolism or anesthesia risk
- Abnormal laboratory values indicating significant clinical abnormalities
- Positive serology for specified infectious diseases
- Known hypersensitivity to related medications
- Recent use of medications interfering with neuromuscular function
- History of mental illness, cognitive impairment, or epilepsy
- Participation in another clinical trial within a specified period
- Any other condition deemed unsuitable by the investigator
- Pregnant or nursing women
- Unwilling to use birth control during the specified period
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
- Taiyuan, Shanxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China; Taiyuan, Shanxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.